Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Otto Grøn Roepstorff

Showing results (1-10 of 2) with videos related to

Pageof 1
Sort By:
Atherosclerosis|August 21, 2025
Risk reduction of ASCVD attributed to lowering of remnant cholesterol from statins, fibrates, APOC3 inhibitors, and ANGPTL3 inhibitors: a cohort studyMie Balling, Otto Grøn Roepstorff, Thomas Alexander Gerds, et al.
Journal of Clinical Lipidology|January 30, 2026
VLDL cholesterol and ASCVD risk: A population-based studyMie Balling, Otto Grøn Roepstorff, Thomas Alexander Gerds, et al.
Pageof 1

Showing results (1-10 of 2) with videos related to

Sort By:
Pageof 1
Atherosclerosis|August 21, 2025
Risk reduction of ASCVD attributed to lowering of remnant cholesterol from statins, fibrates, APOC3 inhibitors, and ANGPTL3 inhibitors: a cohort studyMie Balling, Otto Grøn Roepstorff, Thomas Alexander Gerds, et al.
Journal of Clinical Lipidology|January 30, 2026
VLDL cholesterol and ASCVD risk: A population-based studyMie Balling, Otto Grøn Roepstorff, Thomas Alexander Gerds, et al.
Pageof 1